Expertise in
1
conditions

Agostino Gnasso

Catanzaro, IT 
Expertise in
1
conditions
Catanzaro, IT 

Overview

Agostino Gnasso practices practicing medicine in Catanzaro, Italy.

Mr. Gnasso is highly rated in 1 condition, according to our data. His clinical expertise encompasses Type 1 Diabetes (T1D), Maturity Onset Diabetes of the Young, Type 2 Diabetes (T2D), and Atherosclerosis.

He is actively involved in clinical research, co-authoring 67 peer reviewed articles and participating in 2 clinical trials.

Gender

Male

Locations

Catanzaro, 88100, Italy

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A Randomized, Phase 3, Open-label Trial Comparing the Effect of the Addition of Tirzepatide Once Weekly Versus Insulin Lispro (U100) Three Times Daily in Participants With Type 2 Diabetes Inadequately Controlled on Insulin Glargine (U100) With or Without Metformin (SURPASS-6)
A Randomized, Phase 3, Open-label Trial Comparing the Effect of the Addition of Tirzepatide Once Weekly Versus Insulin Lispro (U100) Three Times Daily in Participants With Type 2 Diabetes Inadequately Controlled on Insulin Glargine (U100) With or Without Metformin (SURPASS-6)
Enrollment Status: Completed
Publish Date: November 02, 2023
Intervention Type: Drug
Study Drugs: Tirzepatide, Insulin Lispro, Insulin Glargine
Study Phase: Phase 3
A Randomized, Phase 3, Open-Label Trial Comparing the Effect of LY3298176 Versus Titrated Insulin Degludec on Glycemic Control in Patients With Type 2 Diabetes
A Randomized, Phase 3, Open-Label Trial Comparing the Effect of LY3298176 Versus Titrated Insulin Degludec on Glycemic Control in Patients With Type 2 Diabetes
Enrollment Status: Completed
Publish Date: January 19, 2022
Intervention Type: Drug
Study Phase: Phase 3
View 1 Less Clinical Trial

67 Total Publications

Empagliflozin might improve chronic inflammatory bowel diseases also in humans.
Empagliflozin might improve chronic inflammatory bowel diseases also in humans.
Journal: Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
Published: September 30, 2025

Frequently Asked Questions about Agostino Gnasso

Is Agostino Gnasso a top-rated expert for Type 1 Diabetes (T1D)?

MediFind is an objective health platform that identifies experts based on real-world data. Agostino Gnasso is classified as an Advanced expert for Type 1 Diabetes (T1D), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Agostino Gnasso participate in research or clinical trials?

Yes. Agostino Gnasso has published 67 articles and abstracts on conditions like Type 1 Diabetes (T1D). You can view a list of Agostino Gnasso's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Gnasso's expertise for a condition
ConditionClose
      View All 8 Experienced Conditions
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile